NEOD 001 development is discontinued for AL Amyloidosis.-Prothena Corpn.

Prothena Corporation plc has announced that the Company is discontinuing development of NEOD 001, an investigational antibody that was being evaluated for the treatment of AL amyloidosis. The decision was based on results from the Phase IIb PRONTO study and a futility analysis of the Phase III VITAL study which did not meet its primary or secondary endpoints, the Company asked the independent data monitoring committee (DMC) of the Phase III VITAL study to review a futility analysis of the ongoing VITAL study. The DMC recommended discontinuation of the VITAL study for futility. The Company therefore decided to discontinue all development of NEOD 001, including the VITAL study as well as the open label extension studies.